Clinical Trial

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, Phase I-II, first-in-human (FIH) study of 9MW2921 in patients with locally advanced or metastatic solid tumors refractory to all standard therapies. The objective of this study is to evaluate the safety, tolerability, PK, immunogenicity and Preliminary Antitumor Activity of 9MW2921.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-04; most recent amendment 2024-11-19.
Status change: Recruiting → Active, Not Recruiting 2024-11-19
Status change: Not Yet Recruiting → Recruiting 2023-08-29
Trial Details
NCT Number NCT05990452
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 261 participants
Start Date 2023-08-28
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-21